Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTZ-043 in Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis
NCT04044001Phase 2Completed
- Start
- Nov 2019
- Primary completion
- Mar 2022
- Modality
- Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of BTZ-043 in pulmonary tuberculosis (TB). Started Nov 2019; status: completed.
02
Drugs
BTZ-043
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT04044001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044001.